LEXINGTON, Mass.--(BUSINESS WIRE)--Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that positive data are being presented by its collaborator Genentech, a member of the Roche Group, from a pivotal Phase II clinical trial conducted by Roche and Genentech of vismodegib (GDC-0449, RG3616) in patients with advanced basal cell carcinoma (BCC), an often life-threatening form of skin cancer that can have disfiguring and debilitating effects. The results will be presented on June 21st at the Seventh European Association of Dermato-Oncology (EADO) Congress taking place in Nantes, France.
